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Summary: Factors affecting the caffeine acetylation phenotype were investigated in a French Caucasian
population of 150 unrelated supposedly healthy subjects, aged 18 to 63 years. This population, including 75
men and 75 women, was used to determine whether the acetylation polymorphism is related to environmental
influences such as smoking habits, intake of alcohol, use of oral contraceptives, use of certain drugs. The
acetylation phenotype was assessed from the molar ratio of two caffeine metabolites: 5-acetylamino-6-
formylamino-3-methyluracil/l-methylxanthine. For values less than 0.85, the subjects were classified as poor
acetylators (frequency, χ ± SD: 61.3 ± 7.9%) in this study. Dose recoveries of 5-acetylamino-6-formylamino-
3-methyluracil (x + SD) were 1.26 ± 0.85% and 3.58 ± 1.64% in slow and rapid acetylators, respectively.
The recovery (x + SD) of 1-methylxanthine in the 3 hour-urine was 2.86 ± 1.51% in slow acetylators and
2.36 ± 1.27% in rapid acetylators. The mean value (and SD) of the molar ratio was 0.437 (0.177) and 1.669
(0.651) for slow and rapid acetylators. Three other metabolite ratios can also provide an acetylation in-
dex: 5-acetylaimno-6-formylaimno-3-methylur + 1 -methyl-
xanthine + 1-methyluricacid; 5-acetylamino-6-formylamino-3-methyluracil/l-methylxanthine + 1-methyluric
acid + 1,7-dimethyluric acid; and 5-acetylamino-6-formylamino-3-methyluracil/l-methylxanthine + 1-methyl-
uric acid + 1,7-dimethyluric acid + 1,7-dimethylxanthine with a bimodal distribution for the former and a
trimodal distribution for the two latter ratios, both showing about 95% concordance with the 5-acetylamino-
6-formylamino-3-methyluracil/l-methylxanthine ratio. Age did not influence the excretion of caffeine and its
five major metabolites. A marked influence of sex was observed only on the unchanged caffeine excretion,
and the effect was greater in slow acetylators than in rapid acetylators. The 5-acetylamino-6-formylamino-3-
methyluracil excretion was about three times higher in rapid acetylators than in slow acetylators in both
sexes.
Introduction
Caffeine or 1,3,7-trimethylxanthine is a very common
substance (present in coffee, tea, chocolate, coca-cola,
etc.). This compound (like isoniazid, sulphadimidine,
or dapsone) can be used for determining the acety-
lation phenotype (1 — 5), and some authors have used
it to assess genotypes (6). In man, the metabolism of
caffeine is rather complicated and follows different
pathways:
— successive oxidations by cytochrome P-450-de-
pendent N-demethylases, giving first 1,7-dime-
thylxanthine, then 1,7-dimethyluric acid by the
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action of the cytochrome P-450-dependent 8-hy-
droxylase. 1,7-dimethylxanthine can be further
metabolized to an unstable intermediate.
transformation of this unknown metabolite by
polymorphic N-acetyltransferase, leading to a ma-
jor acetylated metabolite: 5-acetylamino-6-for-
mylamino-3-methyluracil. Alternatively, N-deme-
thylation of 1,7-dimethylxanthine produces 1-
methylxanthine which is converted by xanthine
oxidase into the hydroxylated metabolite, 1-meth-
yluric acid.
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Interindividual genetically based variations in the
acetylation pathway of caffeine have been described
in humans (6 — 8) and ethnic differences have also
been reported (9).
The classification of subjects into slow or rapid ace-
tylators depends on the urinary excretion ratio
(5-acetylamino-6-formylamino-3-methyluracil/l-meth-
ylxanthine) determined on urine collected during the
3 hours following oral ingestion of caffeine. The slow
acetylator trait is transmitted as a recessive or codom-
inant autosomal trait (10-12, 13) and is linked with
a defective production by the gene of the hepatic N-
acetyltransferase (14). Using caffeine as the test sub-
stance, some authors observed two populations in the
rapid acetylator group, comprising heterozygous and
homozygous subjects (6, 15, 16).
Several protocols based on the use of caffeine as the
metabolic substrate have been proposed in the liter-
ature for determining the three phenotypes. However,
the administered dose, the urinary collection time and
the necessity for a diet without xanthines have been
differently reported (6, 12, 16). In the present work,
after modifying the HPLC method previously de-
scribed by Grant (12, 15), the acetylation phenotype
was explored in a population of 150 unrelated healthy
subjects. The effects of age, sex, use of tobacco, al-
cohol intake and use of oral contraceptives were stud-
ied on the urinary excretion of the different metabo-
lites. In addition, relationships were investigated be-
tween blood constituents (cholesterol, triacylglycerols
and glucose) and the urinary excretion of metabolites.
Materials and Methods
Samples
Blood specimens were collected into Vacutainer Tubes (Becton
Dickinson, Rutherford, NJ) by venipuncture from the cubital
vein of supine fasting subjects. The samples were promptly
centrifuged for 5 min at 3000 g.
Urine samples were collected over the 3-h period immediately
following ingestion of the test substance.
Chromatographie conditions
The urinary concentrations of 5-acetylamino-6-formylamino-3-
rnelhyluracil, 1-methylxanthine, 1-methyluric acid, 1,7-dime-
thylxanthine, 1,7-dimethyluric acid and of unchanged caffeine
(1,3,7-trimethylxanthine) were determined by an HPLC method
previously described by Grant et al. (12, 15) and modified in
our laboratory. The HPLC system consisted of a one solvent
delivery pump (Model 6000 A, Waters Associates, Milford,
MA, USA), a refrigerated auto-injector (Model As-48, Bio-
Rad, Richmond, CA, USA), a UV-visible variable-wavelength
detector (Model 481, Waters) and an integrator (Model CR3A,
Shimadzu, Roucaire, Velizy-Villacoublay, France). The system
was operated at room temperature.
The analytical column was prepacked with Ultraspher ODS,
(5 μηι particle size, 150 mm χ 4.6 mm, Beckman, Paris, France)
and the guard column with LiChrospher 100 RP 18 (5 μηι
particle size, Hibar LiChrocart, Merqlf-Clevenot, Nogent-sur-
Marne, France).
The mobile phase was a mixture of acetic acid 0.5 g/1, volume
fraction 0.12 in methanol. It was filtered through a 0.45 μηι
HV type microfllter (Millipore, Waters Associates) and used at
a flow-rate of 1.0 ml/min.
Twenty μΐ of the urinary sample were automatically injected
into the HPLC system through a six-way injection valve (Rheo-
dyne 7000, Cotati, CA, USA). The UV detection was performed
at 280 nm.
Preparation of the urinary samples
Two hundred μΐ internal standard (N-acetyl-4-aminophenol:
120 g/1 in chloroform, 794 mmol/1) were placed in a glass tube
and evaporated to dryness under a stream of nitrogen (pressure,
200 bars). To the dried residue were added 200 μΐ bidistilled
water, 120 rrig ammonium sulphate and 8 ml chloroform-iso-
propanol mixture (85 + 15 by vol.) The mixture was then
vortexed for 2 minutes and centrifuged for 5 minutes at 2000
min"1.
The aqueous phase was discarded. The chloroformic phase
(about 7 ml) was transferred to another glass-tube and evapo-
rated at 40—45 °C under a stream of nitrogen. The resulting
dried sample was stoppered and frozen at —20 °C until analysis.
Just before analysis, the dried residue was dissolved into 1 ml
mobile phase and 20 μΐ of this solution were injected into the
HPLC system.
Preparation of the standard solutions
The following standard solutions were prepared for the estab^
lishment of calibration curves: 1-methylxanthine (0.482
mmol/1), 1,7-dimethylxan thine (0.444 mmol/1) plus 5-acetylam-
ino-6-formylamino-3-methyluracil (0.222 mmol/1) or 1-methyl-
uric acid (0.275 mmol/l) plus 1,7-dimethyluric acid (0.408
mmol/1).
A 0.08 mol/1 tetraborate disodium buffer adjusted to pH 7 with
1 mol/1 phosphoric acid was used to dissolve the 1-methylUric
acid.
Quantification of the metabolites
Values were expressed per litre of urine. The calibration curves
were established each day covering the range 0 to 221 μηιοΐ/ΐ
for 5-acetylamino-6-formylamino-3-methyluracil, .0 to 275
μιηοΐ/ΐ for 1-methyluric acid, 0 to 482 μηιοΐ/ΐ for 1-methylxan-
thine, 0 to 444 μπιοΐ/ΐ for 1,7-dimethylxanthine, 0 to 408 μτηοΐ/ΐ
for 1,7-dimethyluric acid and 0 to 412 μηιοΙ/1 for l,3,7^trime^
thylxanthine. Every tube was spiked with internal standard (N-
acetyl-4-aminophenol, 0.794 mmol/1 final concentration), and
if necessary with caffeine (0.412 mmol/1).
Statistics
An iterative method of fuzzy sets described by Schroeder (17)
was used to determine whether the population could be a
mixture of different Gaussian subpopulations, and to calculate,
if necessary, the optimal limits of separation of the subpopu-
lations. »
Multiple regression analysis was used to evaluate possible cor-
relations between the different metabolites measured and age,
sex, and certain blood constituents. The concentration of sig-^
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nificance was determined by the F-value at p < 0.001 (10.83).
Student's t-test, Welsh and Fischer-Snedecor tests were also used.
Phenotyping
Adult subjects (> 18 years) took one capsule containing 0.772
μητιοί (150 mg) caffeine monohydrale (Cooperation Pharma-
ceutique Frangaise, Melun, France), and they collected their
urine during the following 3 hours. Urine sample volumes and
pHs were measured. Urines were aliquoted, extracted and
stored al —20 °C until analysis. The urinary pHs must be in
the range of 5.0 to 6.5. If not, urines were discarded.
Acetylalion phenotype was assigned by using the molar ratio
of 5-acetyIamino-6-formylamino-3-methyluraciI and 1-meth-
ylxanthine excreted during 3 hours:
molar ratio =
5-acetylamino-6-formylamino-3-methyruracil (3 h urine)
1-methylxanthine (3 h urine)
Human popula t ion
The study was performed at the Centre for Preventive Medicine
of Vandoeuvre-les-Nancy (France). Healthy unrelated volun-
teers (n = 150) participated in the study which was approved
by the Ethics Committee of Nancy. These 18-to-63 year-old
subjects, 75 men and 75 women (married couples), were fasting
when attending the Centre for Preventive Medicine for a health
examination (18).
Each subject was classified as a slow or rapid acetylator, ac-
cording to whether the value of the molar 5-acetylamino-6-
formy lamino-3-methyluracil/l -met hylxan thine ratio was
< 0.85 or > 0.85, respectively. Subjects under treatment with
drugs known to inhibit or to interfere with the acetylation
phenotype were eliminated from the study. A comparison with
three other acetylation metabolic ratios was performed:
5-acetylamino-6-formylamino-3-methyluracil/5^acetylamino-6-
formylamino-3-methyluracil + 1-methylxanthine + 1-meth-
yluric acid; 5-acetylamino-6-formylamino-3-methyluracil/
1-methylxanthine + 1-methyluric acid + 1,7-dimethyluric
acid; and 5-acetylamino-6-formylamino-3-methyluracil/l-meth-
ylxan thine + 1-methyluric acid + 1,7-dimethylxanthine + 1,7-
dimethyluric acid.
mylamino-3-methyluracil and 1-methylxanthine were
published earlier (18). After 35 days storage at + 4 °C
or — 20 °C, 5-acetylamino-6-formylamino-3-methy-
luracil decreased by 10% or 15%, respectively. 1-
Methylxanthine and 1-methyluric acid decreased by
10% whatever the temperature. But 1,7-dimethyluric
acid and 1,7-dimethylxanthine decreased by 50% after
35 days and 20% after 15 days at + 4 °C or -20 °C.
The analysis of the different metabolites must be
performed in the fifteen days following urine collec-
tion.
Descriptive analysis of the population
The structure of the population is shown in table 1,
and the frequency distribution histograms of the four
ratios suggest two or three separate phenotypic pop-
ulations (fig. 1). These distributions can be modelled
as a mixture of two Gaussian subpopulations repre-
senting slow and rapid acetylators (but not from the
5-acetylamino-6-formylamino-3-methyluracil/5-ace-
tylamino-6-formylamino-3-methyluracil + 1 -meth-
ylxanthine + 1-methyluric acid ratio), or as a mixture
of three Gaussian subpopulations representing ho-
mozygous slow acetylators, heterozygous and homo-
zygous rapid acetylators, based on the 5-acetylamino-
6-formylamino-3-methyluracil/l -methylxanthine and
5-acetylamino-6-formylamino-3-methyluracil/l-meth-
ylxanthine + 1-methyluric acid + 1,7-dimethyluric
acid ratios. Antimodes were statistically determined
at 0.85 and 2.80 for the 5-acetylamino-6-formylam-
ino-3-methyluracil/l-methylxanthine ratio and at 0.29
and 0.58 for the 5-acetylamino-6-formylamino-3-
methyluracil/1-methylxanthine + 1-methyluric acid
+ 1,7-dimethyluric acid ratio.
Results
Analytical variations
Calibration curves are linear for 5-acetylamino-6-for-
mylamino-3-methyluracil up to 221 μπιο1/1(Γ = 1.00);
for 1-methylxanthine, 1,7-dimethylxanthine and 1,7-
dimethyluric acid up to 482, 444, 408 μιηοΐ/ΐ
(r = 1.00); for 1-methyluric acid up to 275 μιηοΐ/ΐ
(r = 1,00) and for 1,3,7-trimethylxanthine up to 412
μηιοΐ/ΐ (r = 1.00). Inter-day coefficients of variation
are 3.8% for 5-acetylamino^6Aformylamino-3-methyl-
uracil; 5.2% for 1-methyluric acid; 7.6% for 1-methyl-
xanthine; 12.0% for 1,7-dimethyluric acid; 9.3% for
1,7-dimethylxanthine; and 11.1% for 1,3,7-trime-
thylxanthine. Coefficients of variation for repeatabil-
ity usually do not exceed 4.1% except for 1-methyl-
xanthine (7.1%) and 1,3,7-trimethylxanthine (9.2%).
Conditions for the storage of 5-acetylamino-6-for-
Tab. 1. Caffeine acetylation in a Caucasian population.
No. (and %)
Slow acetylators Rapid acetylators
N



















χ2 = 1.78 ρ = 0.18 (NS)
Variations according to age and sex
Age did not influence the excretions of caffeine and
of its five major metabolites. But there is an influence
of sex, especially on the 1,3,7-trimethylxanthine ex-
cretion, which is more significant in slow acetylators
than in rapid acetylators (tab. 2). However, the 5-
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Fig. 1. Frequency distributions of the 5-acetylamino-6-formylamino-3-methyluracil/l-methylxanthine ratio and of three other
caffeine metabolite ratios in 150 healthy unrelated Caucasian volunteers.
acetylamino-6-formylamino-3-methyluracil excretion
was lower in women than men in the rapid acetylator
group. 56.0% of the men and 66.7% of the women
were slow acetylators of caffeine (tab. 1).
Effect of drugs and xenobiotics
Drugs (oestrogens, progestative and oral contraceptive
drugs)
Five women were taking oestrogens, 7 used proges-
tative drugs and 6 were taking oral contraceptives.
When these volunteers were considered as a group, it
was shown that the drugs in question did not modify
the excretion of caffeine and its five metabolites.
Xenobiotics
Tobacco and alcohol consumption did not change the
excretion of 5-acetylamino-6-formylamino^methyI-
uracil and 1-methylxanthine and did not affect the
molar ratio S-acetylamino-o-formylainino^S^methyl-
uracil/1-methylxanthine, thus allowing the unambig-
uous assignment of the acetylation phenotype. Nona
of the caffeine metabolites was significantly correlated
with tobacco or alcohol intake among the slow ace-
tylator phenotype. We observed a slight correlation
\τ = 0.198) between 1,3,7-trimethylxanthine and al-
cohol in slow acetylators, — 0465 in rapid acetylators,
and with tobacco (—0.197) in slow acetylators. These
correlations were very close to the limits of signifi-
cance.
Bur. J. Clin. Chem. Clin. Biochem, / Vol. 31,1993 / No. 2
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a) Results are percentages (mean (and SD)) of caffeine ingested
b) N. S.: Not significant
*** = p < 0.001
** = p < 0.01



























































We observed, among adults, a slight correlation be-
tween the concentration of blood glucose and the
urinary excretions of 5-acetylamino-6-formylamino-
3-methyluracil, 1-methyluric acid and 1,3,7-trime-
thylxanthine (r = 0.275,0.298 and 0.193, respectively,
with a threshold value |r| = 0.165). In the group of
slow acetylators, the 5-acetylamino-6-formylamino-3-
methyluracil/1-methylxanthine ratio was positively
correlated with the glucose concentration (r = 0.255;
|r| = 0.210). In the group of rapid acetylators, the
glucose concentration was highly correlated with 5-
acetylamino-6-fonnylamino-3-methyluracil or 1,3,7-
trimethylxanthine (r = 0.349; 0.327; |r| = 0.270). Ad-
justment of glucose concentration on the sex and
Quetelet index (weight per squared height (g/m2)) did
not significantly increase these correlations within the
rapid acetylator group. Triacylglycerols and choles-
terol concentrations showed no correlation with either
caffeine metabolites or the 5-acetylamino-6-formyl-
amino-3-methyiuracil/l -methylxanthine ratio.
Determination of the acetylation phenotype
Using the molar 5-acetylamino-6-formylamino-3-
methyluracil/1-methylxanthine ratio as an index of
the polymorphic N-acetyltransferase activity, the fre-
quency of the slow acetylator trait was determined.
The distribution of the molar metabolite ratio shows
slow acetylators (n = 92) with values between 0 and
0.85; rapid acetylators (n = 58) with values between
0.90 and 3.90. This latter sub-group could be divided
into heterozygous and homozygous rapid acetylators,
i. e. the frequency distribution of the urinary molar
ratio of 5-acetylamino-6-formylamino-3-methylura-
cil/1-methylxanthine was trimodal. The cut-off value
for separation of heterozygous and homozygous rapid
acetylators was 2.80 using the method of fuzzy-sets
(17). Six subjects were rapid homozygous acetylators.
Total dose recoveries of 5-acetylamino-6-formylamr
ino-3-methyluracil and 1-methylxanthine as percent-
age of the ingested caffeine dose were 4.1 % and 5.9%
in slow acetylators and in rapid acetylators, respec-
tively, with a great difference in the 5-acetylamino-6-
formylamino-3-methyluracil excretion of slow and
rapid acetylators (p < 0.001), and a smaller difference
in the 1-methylxanthine excretion (p < 0.05). 5-Ace-
tylamino-6-fonnylamino-3-methyluracil excretion
was lower and 1-methylxanthine excretion higher in
slow acetylators than in rapid acetylators (tab. 3).
Mean dose recoveries (metabolite in % of ingested
caffeine dose) of 1-methyluric acid, 1,7-dimethyluric
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 31,1993 / No. 2
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Tab. 3. Urinary excretions (3 h urine) of 5-acetylamino-6-for-
mylamino-3-methyluracil, 1-methyluric acid, l-meth-
ylxanthine, l ,7-di methyl uric acid, 1,7-dimethylxan-
thine, l ,3,7-trimethylxanthine after oral ingestion of 150
mg caffeine (i. e. 0.772 mmol).











μηιοΙ/3 h 9.69 (6.56) 27.62 (12.69) p < 0.001
Recovery, %*) 1.26 (0.85) 3.58 (1.64) p < 0.001
1-Methyluric acid
μηιο1/31ι 29.27(22.54) 29.94(20.29) N. S.
Recovery, %*) 3.79 (2.92) 3.88 (2.63) N. S.
1-Methylxanthine
μηιο1/3Η 22.08(11.63) 18.19 (9.83) N.S.
Recovery, %*) 2.86 (1.51) 2.36 (1.27) p < 0.05
1,7-Dimethyluric acid
μπκ>1/31ι 16.59(14.00) 19.33(11.62) N.S.
Recovery, %*) 2.14 (1.82) 2.50 (1.50) N.S.
l ,7-Dimethylxan thine
μπκ>1/3Γι 18.85(15.09) 20.56(11.92) N.S.
Recovery, %*) 2.44 (1.95) 2.66 (1.54) N.S.
l ,3,7-Trimethylxanthine
μπκ>1/31ι 8.00 (6.32) 9.72 (8.59) N.S.







1.669 (0.651) p < 0.001
0.447 (0.356) p < 0.001
*) Substance, fraction of caffeine ingested
acid, 1,7-dimethylxanthine and 1,3,7-trimethylxan-
thine were similar between the two phenotypes. The*
3-h urine excretion of these 3 metabolites and of
unchanged caffeine was 9.4% and 10.3%, respec-
tively, for slow and rapid acetylators, and the total
mean values of urinary outputs of the five major
metabolites of caffeine and of native caffeine was
13.67% for the slow acetylator phenotype and
16.25% for the rapid acetylator phenotype (tab. 3),
corresponding to 105.5 μιηοΐ (19.6 mg) and 125.4
μιηοΐ (24.1 mg) for slow and rapid acetylators. Mean
values (and SD) for the 5-acetylamino-6-formyl-
amino-3-methyluracil/l-methylxanthine ratio were
0.437 (0.177) and 1.669 (0.651) for the slow and rapid
acetylators.
Among the studied population, 61.3% of the subjects
were classified as slow acetylators and 38.7% as rapid
acetylators, accepting that such a classification cor-
responds to the properties of a major locus with two
codominant alleles, as suggested by Butler et al. (13)
and Vincent- Viry et al. (20). The frequency of the slow
acetylator allele was estimated to be 0.783 and that
of the rapid acetylator allele 0.217. The expected
genotypic frequencies, calculated according to the
Hardy-Weinberg law, were: hpmozygous slow acety-
lators SS (q2) 0.613; heterozygous rapid acetylators
SR (2pq) 0.340; homozygous rapid acetylators
RR (p2) 0.047. Further studies must be done using
segregation analysis to elucidate this point. For the
ratios 5-acetylamino-6-formylamino-3-methyluracil/
1-methylxanthine + 1-methyluric acid 4- 1,7-dime-
thyl ric acid and 5-acetylamino-6-formylaniino-3-
methyluracil/1-methylxanthine + 1-methyluric acid
+ 1,7-dimethylxanthine + 1,7-dimethyluricacid, the
cut-off values for assignment of phenotype were re-
spectively 0.29 and 0.22 with 94.7% and 94.0% of
concordance between these two ratios and the
5-acetylamino-6-formylaniino-3-methyluracil/l-meth-
ylxanthine ratio. The first ratio identified 59% as slow
acetylators and 41 % as rapid acetylators, the second
ratio 58.7% as slow acetylators and 41.3% as rapid
acetylators.
The allelic frequencies for the allele controlling the
slow acetylator trait were 0.768 and 0.766, based on
the 5-acetylamino-6-fprmylamino-3-methyluracil/l -
methylxanthine + 1-methyluric acid + 1,7-dimethyl-
uric acid and 5-acetylamino-6-fonnylamino-3-meth-
yluracil/1-methylxanthine + 1-methyluric acid + 1,7-
dimethylxanthine + 1,7-dimethyluric acid ratios, re-
spectively. These results were very close to the pro-




In order to support the hypothesis that the acetylation
phenotype is the result of a codominant transmission
of the alleles, we examined the 75 nuclear families of
the 75 couples used to study the 5-acetylamino-
6-formylamino-3-methyluracil/l -methylxanthine and
5-acetylamino-6-formylamino-3-inethyluracil/l^meth^
ylxanthine -f 1-methyluric acid + 1,7-dimethyluric
acid urinary ratios. If the acetylation capabilities de-
scribed by these ratios were inherited by Mendeli&n
transmission, the observed phenotypes of children
must correspond to those expected by classical Men-
delian segregation (tab. 4). Chi-square tests, not sig-
nificant for the two ratios, proved the similarities
between observed values and those expected by clas-
sical Mendelian segregation. However, table 4 shows
that the use of the cut-off values given by the method
of fuzzy-sets led to the wrong classification of two
children (5-acetylamino-6-formylamino-3*methylura-
Eur. J. Clin. Chem. Clin. Biochem. / Vol. 31,1993 / No. 2
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Tab. 4. Observed matings and resulting phenotypes of offspring compared with expected values
Matings Number of Number of
matings children
Offspring
Observed phenotypes Expected phenotypes
SS RS RR SS RS
b) 5-Acetylamino-6-formylamino-3-methyluracil/l -methylxanthine + 1-methyluric acid + 1,7-dimethyluric acid ratio
RR



































































































































The cut-off values used to divide the population into slow (SS) and rapid (RR, RS) acetylators were statistically determined by
the method of fuzzy-sets i.e. 0.85 and 2.80 for a) and 0.29 and 0.58 for b) (16).
* misclassified
cil/1-methylxanthine) and eight children (5-acetylam-
ino-6-formylamino-3-methyluracil/l-methylxanthine
+ 1-methyluric acid + 1,7-dimethyluric acid). In
addition, the two types of assessment of the acetyla-
tion phenotype gave different results for 11 genotypic
matings.
Discussion
Acetylation polymorphism in humans is the result of
a different expression of the activity of the human
liver N-acetyltransferase. The slow acetylation capac-
ity was found to be associated with a decrease in the
quantity of immunodetectable N-acetyltransferase
protein in liver cytosol (14). A cDNA for the poly-
morphic N-acetyltransferase (NAT) was used by Blum
et al. (21) in a restriction mapping, which identified
three non^overlapping clusters called N ATI, NAT2
and NATP.
Assuming that these enzyme activities are responsible
for the acetylation polymorphism, it is possible that
their activities are affected by various biological con-
ditions e.g. age, sex, overweight or environmental
influences such as tobacco or alcohol intake, thereby
modifying the expression of the phenotype.
The total excretion of caffeine and its metabolites
seemed to be higher in men than in women (tab. 2).
This result is in agreement with that of Griffiths et al.
(22) who suggested that men may be more sensitive
to caffeine than women. We have to keep in mind the
possible differences due to pharmacokinetic charac-
teristics. We found no age effect on caffeine metabolite
excretion, and age did not modify the expression of
the acetylation phenotype in this population. How-
ever the effect of age on the acetylation phenotype
appears controversial. Some authors (11, 23, 24)
showed no significant difference in the distribution of
the acetylation phenotype according to age, whereas
Gachalyiet al. (25) demonstrated that there were more
slow acetylators amongst elderly Hungarians than in
a younger population. Indeed, it is well known that
the caffeine metabolism pathway shows maximal ac-
tivity only during infancy (26). A recent review of N-
acetyltransferases (27) discusses the effect of age on_
acetylation polymorphism. After considering many
studies, the author concluded that there is a diminu-
tion of acetylating capacity with age but this is insuf-
ficient to modify the interpretation of a phenotype.
However it is known that persons over 65 years have
a different antimodal value for the separation of phe-
notypes and that children before 6 years can change
their phenotype. These considerations justify the
choice of our adult population with an age range of
18 — 63 years.
Among the women, only 18 subjects took drugs (oes-
trogen and progestative drugs). These drugs did not
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change the distribution of the acetylator status and
did not interfere with phenotyping or N-acetyltrans-
ferase activity.
Tobacco did not influence the acetylation phenotype
based on the 5-acetylamino-6-formylamino-3-methyl-
uracil/J-methylxanthine ratio, and no correlation was
observed between the excretions of the five major
caffeine metabolites and tobacco consumption. We
found a slight diminution of the quantity of un-
changed caffeine (1,3,7-trimethylxanthine) among
smokers compared with non-smokers and ex-smokers.
The means (and SD) were respectively 6.23 (6.09),
10.53 (7.78), and 7.08 (5.51) μπιοΙ/3 h with a F-value
equal to 5.75 (P < 0.025).
Arylamine chemicals in cigarette smoke have been
implicated in the aetiology of some cancers (28, 29)
and some diseases. There is some relationship between
the acetylation phenotype and the risk of developing
a disease or cancer. In the case of bladder cancer, N-
hydroxymetabolites are formed by the action of cy-
tochrome P-450 1A2, which is responsible for the 3-
demethylation of caffeine and the N-oxidation of
carcinogenic arylamines (7, 30). In contrast to to-
bacco, alcohol consumption seems to decrease the
rate of 3-demethylation of caffeine.
The concentration of blood glucose was similar in the
two phenotypes e. g. 5.33 + 0.498 and 5.48 ± 0.933
mmol/1 respectively in slow and in rapid acetylators.
We observed positive correlation with the 5-acetylam-
ino-6-formylamino-3-methyluracil/l-methylxanthine
ratio in the slow acetylator group but not in the rapid
acetylator group.
Indeed, in the rapid acetylators the glucose concen-
tration was correlated with 5-acetylamino-6-formy-
lamino-3-methyluracil, 1-methyluric acid and 1,3,7-
trimethylxanthine. Some authors have reported a re-
lationship between the high frequency of rapid ace-
tylators among diabetes mellitus type I subjects (31).
Price Evans (27) in his very recent review reported
that glucose accelerates the metabolism of acetylated
compounds by increasing the concentration of acetyl-
CoA.
The acetylation phenotype was assessed using the
5-acetylamino-6-formylamino-3-methyluracil/l-meth-
ylxanthine molar ratio. In this study, slow acetylators
had a value lower than 0.85. This first cut-off value
is the optimal limit of separation between two Gauss-
ian subpopulations; it was calculated by the iterative
method of fuzzy-sets (17) and it differs slightly from
that used in the literature (6, 7, 8, 16). The frequency
of the allele controlling the slow acetylator phenotype
was estimated to be 0.783, giving 61.3% subjects
classified as slow acetylators (95% confidence interval
53.4% to 69.2%). This frequency of the allele con-
trolling the slow acetylator phenotype is in agreement
with those found in the literature for Caucasian pop-
ulations (6, 8). The frequency distribution for the 5-
acetylamino-6-formylamino-3-methyluracil/l-meth-
ylxanthine ratio showed clearly two subgroups, and
in the rapid acetylator group it showed the hetero-
zygotes and the homozygotes for this codominant
trait. This must be confirmed by a statistical pedigree
analysis to ensure that the 6 subjects with a 5-acetyl-
amino-6-formylamino-3-methyluracil/l-methylxan-
thine ratio value greater than 2.8 were true homozy-
gous rapid acetylators. This result is in agreement
with some other studies which identified three modes
(6, 12, 16). The present study identified clearly three
distinct groups, the variabilities of which were quite
different and particularly large in the rapid acetylator
group.
The distribution of the S-acetylamino-o-fqrmylamino^
3-methyluracil/5-acetylamino-6-formylamino^3-meth-
yluracil + 1-methylxanthine + 1-methyluric acid ra-
tio seemed to be bimodal, but it does not enable the
differentiation of the slow from the rapid acetylators.
For the two other ratios, the observed frequencies for
the allele controlling the slow acetylator phenotype
were very close to that obtained with the use of the
5-acetylamino-6-formylamino-3-methyluracil/l-meth-
ylxanthine ratio for the acetylation phenotype deter-
mination. Pedigree analyses based on two metabolic




methyluric acid + 1,7-dimethylxanthine ratios. The
S-acetylamino-o-formylamino-S-methyluracil/l-meth-
ylxanthine + 1-methyluric acid + 1,7-dimethyluric
acid + 1,7-dimethylxanthine ratio should be dis-
carded for the determination of the acetylation phe-
notype.
A few subjects were misclassified, implying that these
two ratios can be employed for acetylator phenotype
determination without misclassifying slow acetylators
as fast acetylators.
The results support the idea that it could be useful in
a Centre of Preventive Medicine to phenotype some
patients in order to inform them about potential risks
related to their acetylation phenotype. We found a
allelic frequency of 0.783 for the allele controlling the
slow acetylator phenotype. Age, sex, overweight (Que-=
telet index), environmental influences such as tobacco
smoke, moderate alcohol intake and certain drugs do
not affect the expression of the acetylation phenotype
based on the 5-acetylamino-6-formylamino-3-methyl-
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uracil/1-methylxanthine ratio. The use of the 5-acetyl-
amino-6-formylamino-3-methyluracil/l-methylxanthi-
ne + 1-methyluricacid + l ,7-dimethyluric acid ratio
to determine the acetylation phenotype, could be of
interest for monitoring the acetylation phenotype ob-
tained by the 5-acetylamino-6-formylamino-3-meth-
yluracil/1-methylxanthine ratio, especially if the value
is close to the cut-off value. This study validates the
use of the 5-acetylamino-6-formylamino-3-methylur-
acil/1-methylxanthine ratio to determine the acetyla-
tion phenotype, i. e. the histogram was trimodal. With
the exception of only 2 children, the offspring were
also correctly phenotyped by this ratio.
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